Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting DNA gyrase.

John F Barrett1

  • 1Bristol-Myers Squibb, Department of Infectious Diseases - Microbiology, 5 Research Parkway, Wallingford, CT 06492, USA. John.Barrett@bms.com

Expert Opinion on Therapeutic Targets
|January 24, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibacterial and mechanism of action studies of boxazomycin A.

The Journal of antibiotics·2024
Same author

Overview of anti-infective drug development.

Current protocols in pharmacology·2011
Same author

Thiazomycins, thiazolyl peptide antibiotics from Amycolatopsis fastidiosa.

Journal of natural products·2009
Same author

Isolation, structure, and antibacterial activity of thiazomycin A, a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa.

Bioorganic & medicinal chemistry·2008
Same author

Isolation, structure, and antibacterial activity of philipimycin, a thiazolyl peptide discovered from Actinoplanes philippinensis MA7347.

Journal of the American Chemical Society·2008
Same author

Control and prevention of MRSA infections.

Methods in molecular biology (Clifton, N.J.)·2007
Same journal

The biological role of CCR4 and its ligands CCL17 and CCL22 in atopic dermatitis: therapeutic implications and future directions.

Expert opinion on therapeutic targets·2026
Same journal

Hepatocyte nuclear factor 4α - prospects for therapeutic targeting.

Expert opinion on therapeutic targets·2026
Same journal

The role of bile acid receptors in cholestatic liver disease: pathophysiological insights and therapeutic advances.

Expert opinion on therapeutic targets·2026
Same journal

Molecular insights for targeting the Nrf1 pathway in hepatocellular carcinoma.

Expert opinion on therapeutic targets·2026
Same journal

Transient receptor potential (TRP) channels: an emerging therapeutic target for the treatment of cardiac hypertrophy.

Expert opinion on therapeutic targets·2026
Same journal

The AT<sub>2</sub> receptor as a potential target for autosomal dominant polycystic kidney disease therapy?

Expert opinion on therapeutic targets·2026
See all related articles

Microcin B17 (MccB17), a peptide DNA gyrase inhibitor, has an unknown mechanism of action. This study definitively elucidates MccB17

Area of Science:

  • Microbiology
  • Molecular Biology
  • Biochemistry

Background:

  • The peptide microcin B17 (MccB17) was discovered in the early 1990s as a DNA gyrase inhibitor.
  • Its precise mechanism of action has remained elusive, hindering the development of new peptide-based antibiotics.
  • MccB17 offers a unique chemical scaffold for novel antibacterial agents.

Purpose of the Study:

  • To definitively determine the mechanism of action of microcin B17 (MccB17).
  • To provide a basis for the synthesis of new semisynthetic analogues of MccB17.
  • To compare MccB17's activity with other DNA gyrase inhibitors and bacterial toxins.

Main Methods:

  • Enzyme inhibition assays to assess DNA gyrase activity.
  • Bacterial growth inhibition studies.

Related Experiment Videos

  • Comparative analysis of MccB17 with quinolones, Ca(2+)-mediated effects, and CcdB.

    • Main Results:

    • Definitive data on MccB17's mode of inhibition against DNA gyrase.
    • Insights into MccB17's unique inhibitory profile compared to other agents.
    • Potential for MccB17 chemotype in developing new antibacterial drugs.

    Conclusions:

    • The mechanism of action of MccB17 has been definitively elucidated.
    • This research opens avenues for semisynthetic analogue development.
    • MccB17 presents a distinct inhibitory profile relevant to antibiotic research.